Search research articles
Contact Us
Filters
Showing results (1-10 of 196) with videos related to
Page
of 20
Sort By:
Journal of Hepatology
|
May 8, 2022
Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'
Georg Semmler, Mattias Mandorfer
Hepatology (Baltimore, Md.)
|
May 1, 2024
The fade-out of HCV coinfection in people who live with HIV
Georg Semmler, Mattias Mandorfer
European Journal of Radiology
|
December 14, 2020
Letter to Lavian and colleagues
Georg Semmler, Thomas Reiberger
JHEP Reports : Innovation in Hepatology
|
December 30, 2025
Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
Mattias Mandorfer, Georg Semmler
Hepatobiliary Surgery and Nutrition
|
December 12, 2025
Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension
Georg Semmler, Mathias Jachs, Mattias Mandorfer
Clinical and Molecular Hepatology
|
January 6, 2025
Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis"
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 16, 2022
Reply
Georg Semmler, Thomas Reiberger, Bernhard Scheiner
JHEP Reports : Innovation in Hepatology
|
June 20, 2026
Reply to: "Are FIB-4 and liver stiffness measurement interchangeable for HCC risk stratification in MASLD?"
Georg Semmler, Jan Embacher, Mattias Mandorfer
Clinical and Molecular Hepatology
|
February 17, 2025
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis"
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clinical and Molecular Hepatology
|
December 14, 2022
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Page
of 20
Search research articles
Search
Showing results (1-10 of 196) with videos related to
Sort By:
Page
of 20
Journal of Hepatology
|
May 8, 2022
Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'
Georg Semmler, Mattias Mandorfer
Hepatology (Baltimore, Md.)
|
May 1, 2024
The fade-out of HCV coinfection in people who live with HIV
Georg Semmler, Mattias Mandorfer
European Journal of Radiology
|
December 14, 2020
Letter to Lavian and colleagues
Georg Semmler, Thomas Reiberger
JHEP Reports : Innovation in Hepatology
|
December 30, 2025
Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
Mattias Mandorfer, Georg Semmler
Hepatobiliary Surgery and Nutrition
|
December 12, 2025
Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension
Georg Semmler, Mathias Jachs, Mattias Mandorfer
Clinical and Molecular Hepatology
|
January 6, 2025
Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis"
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 16, 2022
Reply
Georg Semmler, Thomas Reiberger, Bernhard Scheiner
JHEP Reports : Innovation in Hepatology
|
June 20, 2026
Reply to: "Are FIB-4 and liver stiffness measurement interchangeable for HCC risk stratification in MASLD?"
Georg Semmler, Jan Embacher, Mattias Mandorfer
Clinical and Molecular Hepatology
|
February 17, 2025
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis"
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clinical and Molecular Hepatology
|
December 14, 2022
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Page
of 20